Dec 23 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved Acer Therapeutics Inc's drug for treating patients with a type of genetic disorder called urea cycle disorders, according to the health regulator's website. (Reporting by Raghav Mahobe in Bengaluru; Editing by Anil D'Silva)